Clinical Trial Update: Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas [Phase 1]

View source ↗

Summary

Phase 1 study of ganetespib with ziv-aflibercept in refractory gastrointestinal cancer, non-small cell lung cancer (non-squamous), urothelial cancer, and sarcom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancer
• Non-small Cell Lung Cancer
• Sarcoma
• Urothelial Cancer

Drugs mentioned

• Ganetespib (ganetespib)
• Zaltrap (ramucirumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neoplasms | Phase 1 | Status: TERMINATED | Results posted: 2018-01-30